nach oben

Drugs

Erschienen in:

04.07.2023 | Review Article

New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma

verfasst von: John D. Gordan, Bridget P. Keenan, Huat Chye Lim, Mark Yarchoan, R. Katie Kelley

Erschienen in: Drugs | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally and is rising in incidence. Until recently, treatment options for patients with advanced stages of HCC have been limited to antiangiogenic therapies with modest improvements in overall survival. The emerging role of immunotherapy with immune checkpoint inhibitors (ICI) in oncology has led to a rapid expansion in treatment options and improvements in outcomes for patients with advanced stages of HCC. Recent clinical trials have shown meaningful survival improvement in patients treated with the combination of bevacizumab and atezolizumab, as well as with the combination of tremelimumab with durvalumab, resulting in regulatory approvals of these regimens as frontline therapy. Beyond improvements in overall survival, ICI-based combination regimens achieve higher rates of durable treatment response than multikinase inhibitors and have favorable side effect profiles. With the emergence of doublet anti-angiogenic and immune checkpoint inhibitor (ICI) and dual ICI combinations, individualized therapy is now possible for patients based on co-morbidity profiles and other factors. These more potent systemic therapies are also being tested in earlier stages of disease and in combination with loco-regional therapies such as trans-arterial chemoembolization and stereotactic body radiotherapy. We summarize these advances and emerging therapeutic combinations currently in clinical trials.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Llovet JM, Hilgard P, de Oliveira AC, Forner A, Zeuzem S, Galle PR, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.CrossRefPubMed

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002.CrossRefPubMedPubMedCentral

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.CrossRefPubMed

Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96. https://doi.org/10.1016/S1470-2045(18)30937-9.CrossRefPubMed

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745.CrossRefPubMed

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2100070.CrossRef

Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91. https://doi.org/10.1001/jamaoncol.2017.3055.

10.

Vogel A, Martinelli E, Vogel A, Cervantes A, Chau I, Daniele B, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(6):801–5. https://doi.org/10.1016/j.annonc.2021.02.014.CrossRefPubMed

11.

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47(10):1187–93. https://doi.org/10.1038/ng.3389.CrossRefPubMed

12.

Ye J, Li TS, Xu G, Zhao YM, Zhang NP, Fan J, et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. Cancer Res. 2017;77(19):5287–300. https://doi.org/10.1158/0008-5472.CAN-17-0229.CrossRefPubMed

13.

Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 2010;52(4):550–9. https://doi.org/10.1016/j.jhep.2010.01.015.CrossRefPubMedPubMedCentral

14.

Pilati C, Letouze E, Nault JC, Imbeaud S, Boulai A, Calderaro J, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25(4):428–41. https://doi.org/10.1016/j.ccr.2014.03.005.CrossRefPubMed

15.

Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327-41 e23. https://doi.org/10.1016/j.cell.2017.05.046.

16.

Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46(12):1267–73. https://doi.org/10.1038/ng.3126.CrossRefPubMed

17.

Lim HC, Gordan JD. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Comput Biol. 2021;17(2): e1008699. https://doi.org/10.1371/journal.pcbi.1008699.CrossRefPubMedPubMedCentral

18.

Sung W-K, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–9. https://doi.org/10.1038/ng.2295.CrossRefPubMed

19.

Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–101. https://doi.org/10.1016/j.jhep.2016.02.021.CrossRefPubMed

20.

Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84. https://doi.org/10.1136/gutjnl-2015-309809.CrossRefPubMed

21.

Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, et al. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016;122(16):2512–23. https://doi.org/10.1002/cncr.30103.CrossRefPubMed

22.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. https://doi.org/10.1002/hep.29086.CrossRefPubMed

23.

Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–9. https://doi.org/10.1136/gutjnl-2013-306228.CrossRefPubMed

24.

Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect. 2016;22(10):826–32. https://doi.org/10.1016/j.cmi.2016.08.025.CrossRefPubMedPubMedCentral

25.

Ramage HR, Kumar GR, Verschueren E, Johnson JR, Von Dollen J, Johnson T, et al. A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol Cell. 2015;57(2):329–40. https://doi.org/10.1016/j.molcel.2014.12.028.CrossRefPubMedPubMedCentral

26.

Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017. https://doi.org/10.1016/j.jhep.2017.08.030.CrossRefPubMedPubMedCentral

27.

Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, et al. Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response. Hepatol Commun. 2021;5(7):1290–9. https://doi.org/10.1002/hep4.1716.CrossRefPubMedPubMedCentral

28.

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204–12. https://doi.org/10.1016/j.jhep.2017.07.025.CrossRefPubMed

29.

Kondili LA, Quaranta MG, Cavalletto L, Calvaruso V, Ferrigno L, D’Ambrosio R, et al. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. Dig Liver Dis. 2023. https://doi.org/10.1016/j.dld.2023.01.153.CrossRefPubMed

30.

Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–11. https://doi.org/10.1038/ng.3252.CrossRefPubMedPubMedCentral

31.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9(12):1696–707. https://doi.org/10.1158/2159-8290.CD-19-0555.CrossRefPubMed

32.

Zhang W, He H, Zang M, Wu Q, Zhao H, Lu LL, et al. Genetic features of aflatoxin-associated hepatocellular carcinoma. Gastroenterology. 2017;153(1):249-62 e2. https://doi.org/10.1053/j.gastro.2017.03.024.CrossRefPubMed

33.

Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73. https://doi.org/10.1016/j.jhep.2021.11.030.CrossRefPubMed

34.

Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim T-Y, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001. https://doi.org/10.1016/S1470-2045(21)00151-0.CrossRefPubMed

35.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

36.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMed

37.

Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–45. https://doi.org/10.1200/JCO.20.02672.CrossRefPubMed

38.

Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, Version 22021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2021;19(5):541–65. https://doi.org/10.6004/jnccn.2021.0022.CrossRefPubMed

39.

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90. https://doi.org/10.1016/S1470-2045(21)00252-7.CrossRefPubMed

40.

Qin S, Chan LS, Gu S, Bai Y, Ren Z, Lin X, et al. LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol. 2022;33:S1401–2. https://doi.org/10.1016/j.annonc.2022.08.032.CrossRef

41.

Qin S, Kudo M, Meyer T, Finn RS, Vogel A, Bai Y, et al. LBA36 final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann Oncol. 2022;33:S1402–3. https://doi.org/10.1016/j.annonc.2022.08.033.CrossRef

42.

Kelley RK, Rimassa L, Cheng A-L, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. https://doi.org/10.1016/S1470-2045(22)00326-6.CrossRefPubMed

43.

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. LBA34 Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:S1401. https://doi.org/10.1016/j.annonc.2022.08.031.CrossRef

44.

Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, et al. Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: how does adherence to the IMbrave150 trial inclusion criteria impact prognosis? Target Oncol. 2023;18(2):221–33. https://doi.org/10.1007/s11523-023-00953-x.CrossRefPubMed

45.

Larrey E, Campion B, Evain M, Sultanik P, Blaise L, Giudicelli H, et al. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC. Liver Int. 2022;42(12):2843–54. https://doi.org/10.1111/liv.15458.CrossRefPubMed

46.

Pizuorno Machado A, Shatila M, Liu C, Wang J, Altan M, Zhang HC, et al. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. J Cancer Res Clin Oncol. 2023. https://doi.org/10.1007/s00432-023-04582-9.CrossRefPubMed

47.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38(6):576–83. https://doi.org/10.1200/JCO.19.01674.CrossRefPubMed

48.

Grover S, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, et al. Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract. 2020;16(9):e933–42. https://doi.org/10.1200/JOP.19.00672.CrossRefPubMed

49.

Kayali S, Pasta A, Plaz Torres MC, Jaffe A, Strazzabosco M, Marenco S, et al. Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis. Liver Int. 2023;43(1):8–17. https://doi.org/10.1111/liv.15419.CrossRefPubMed

50.

Runger A, Schadendorf D, Hauschild A, Gebhardt C. Immune checkpoint blockade for organ-transplant recipients with cancer: a review. Eur J Cancer. 2022;175:326–35. https://doi.org/10.1016/j.ejca.2022.08.010.CrossRefPubMed

51.

Vogel A, Lleo A. Immune checkpoint inhibitors in malignancies after liver transplantation: better safe or sorry? Liver Int. 2023;43(1):6–7. https://doi.org/10.1111/liv.15474.CrossRefPubMed

52.

D’Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology. 2022;76(4):1000-12. https://doi.org/10.1002/hep.32468.

53.

Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022;52(9):773–83. https://doi.org/10.1111/hepr.13797.CrossRefPubMed

54.

Jost-Brinkmann F, Demir M, Wree A, Luedde T, Loosen SH, Muller T, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort. Aliment Pharmacol Ther. 2023. https://doi.org/10.1111/apt.17441.CrossRefPubMed

55.

Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta-Rivera M, et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600–9. https://doi.org/10.1016/j.jhep.2021.04.047.CrossRefPubMed

56.

Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer. 2019;125(18):3234–41. https://doi.org/10.1002/cncr.32206.CrossRefPubMed

57.

Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49(10):1323–33. https://doi.org/10.1111/apt.15245.CrossRefPubMedPubMedCentral

58.

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. https://doi.org/10.1016/S1470-2045(21)00604-5.CrossRefPubMed

59.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96. https://doi.org/10.1016/S1470-2045(18)30937-9.CrossRefPubMed

60.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–204. https://doi.org/10.1001/jamaoncol.2019.1549.CrossRefPubMedPubMedCentral

61.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2.CrossRefPubMedPubMedCentral

62.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52. https://doi.org/10.1016/S1470-2045(18)30351-6.CrossRefPubMed

63.

Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehi M, Miho M, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2023;164(1):72-88 e18. https://doi.org/10.1053/j.gastro.2022.09.005.CrossRefPubMed

64.

Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–9. https://doi.org/10.1016/j.jhep.2020.07.026.CrossRefPubMedPubMedCentral

65.

Neely JY, Kudo M, et al., editor. Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial. New Orleans: American Association for Cancer Research; 2022.

66.

Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599–611. https://doi.org/10.1038/s41591-022-01868-2.CrossRefPubMed

67.

Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–6. https://doi.org/10.1038/s41586-021-03362-0.PubMedPMID:33762733;PMCID:8046670.CrossRefPubMedPubMedCentral

68.

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202. https://doi.org/10.1200/JCO.19.01307.CrossRefPubMed

69.

Kelley RK, Greten TF. Hepatocellular carcinoma—origins and outcomes. N Engl J Med. 2021;385(3):280–2. https://doi.org/10.1056/NEJMcibr2106594.CrossRefPubMed

70.

Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019;15(16):1811–22. https://doi.org/10.2217/fon-2019-0097.CrossRefPubMed

71.

Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M, et al. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res. 2018;48(6):442–50. https://doi.org/10.1111/hepr.13048.CrossRefPubMed

72.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11081084.CrossRefPubMedPubMedCentral

73.

Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117–27. https://doi.org/10.1200/JCO.22.00392.CrossRefPubMed

74.

Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013. https://doi.org/10.1038/s41419-020-03221-2.CrossRefPubMedPubMedCentral

75.

Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013;57(4):1448–57. https://doi.org/10.1002/hep.26153.CrossRefPubMed

76.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–51. https://doi.org/10.1016/j.jhep.2016.10.029.CrossRefPubMed

77.

De Lombaerde E, De Wever O, De Geest BG. Delivery routes matter: safety and efficacy of intratumoral immunotherapy. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188526. https://doi.org/10.1016/j.bbcan.2021.188526.CrossRefPubMed

78.

Chen M, Chow PKH, Kaseb AO, Lee HC, Yopp AC, Becker L, et al. Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. J Clin Oncol. 2023;41(16_suppl):4002. https://doi.org/10.1200/JCO.2023.41.16_suppl.4002.CrossRef

79.

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219–29. https://doi.org/10.1016/S2468-1253(21)00385-X.CrossRefPubMedPubMedCentral

80.

Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208–18. https://doi.org/10.1016/S2468-1253(21)00427-1.CrossRefPubMedPubMedCentral

81.

Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2(9):891–903. https://doi.org/10.1038/s43018-021-00234-4.CrossRefPubMedPubMedCentral

82.

Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–99. https://doi.org/10.1158/2159-8290.CD-16-0577.CrossRefPubMed

83.

Patel S, Othus M, Prieto V, Lowe M, Buchbinder E, Chen Y, et al. LBA6 neoadjvuant versus adjuvant pembrolizumab for resected stage III–IV melanoma (SWOG S1801). Ann Oncol. 2022;33:S1408. https://doi.org/10.1016/j.annonc.2022.08.039.CrossRef

84.

Ho WJ, Sharma G, Zhu Q, Stein-O’Brien G, Durham J, Anders R, et al. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-000932.CrossRefPubMedPubMedCentral

85.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267. https://doi.org/10.1200/JCO.2021.39.3_suppl.267.CrossRef

86.

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. https://doi.org/10.1056/EVIDoa2100070.CrossRef

87.

Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11): e204564. https://doi.org/10.1001/jamaoncol.2020.4564.CrossRefPubMedPubMedCentral

88.

Finn RSKM, Merle P et al., editor. Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma. Paris: 2022 European Society of Medical Oncology; 2022.

89.

El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021;98:102221. https://doi.org/10.1016/j.ctrv.2021.102221.CrossRefPubMed

90.

Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, et al. Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials. Front Oncol. 2021;11: 752725. https://doi.org/10.3389/fonc.2021.752725.CrossRefPubMedPubMedCentral

91.

Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial. J Clin Oncol. 2023;41(9):1747–57. https://doi.org/10.1200/JCO.22.00972.CrossRefPubMed

92.

Ryoo B-Y, Hsu C-H, Li D, Burgoyne A, Cotter C, Badhrinarayanan S, et al. Results from the MORPHEUS-liver study: phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). J Clin Oncol. 2023;41(16_suppl):4010. https://doi.org/10.1200/JCO.2023.41.16_suppl.4010.CrossRef

93.

Kelley RK, Cheng A-L, Kaseb A, Qin S, Zhu AX, Chan S, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Gomez Rangel JD, Merle P, Benzaghou FM, Banerjee K, Hazra S, Fawcett J, Rimassa L. VP10-2021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.10.008.CrossRef

94.

Yang Y, Jin G, Pang Y, Huang Y, Wang W, Zhang H, et al. Comparative efficacy and safety of nivolumab and nivolumab plus ipilimumab in advanced cancer: a systematic review and meta-analysis. Front Pharmacol. 2020;11:40. https://doi.org/10.3389/fphar.2020.00040.CrossRefPubMedPubMedCentral

95.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 2017;7(7):750–65. https://doi.org/10.1158/2159-8290.CD-16-0778.CrossRefPubMedPubMedCentral

96.

Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells. Cancer Discov. 2021;11(5):1100–17. https://doi.org/10.1158/2159-8290.CD-20-1445.CrossRefPubMed

97.

Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, et al. Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule. Cell Rep Med. 2020;1(9): 100163. https://doi.org/10.1016/j.xcrm.2020.100163.CrossRefPubMedPubMedCentral

98.

Bai L, Sun M, Xu A, Bai Y, Wu J, Shao G, et al. Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma. J Clin Oncol. 2021;39(15_suppl):4101. https://doi.org/10.1200/JCO.2021.39.15_suppl.4101.CrossRef

99.

Xing B, Da X, Zhang Y, Ma Y. A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): updated efficacy and safety results. J Clin Oncol. 2022;40(16_suppl):4115. https://doi.org/10.1200/JCO.2022.40.16_suppl.4115.CrossRef

100.

Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, et al. Abscopal benefits of localized radiotherapy depend on activated T-cell trafficking and distribution between metastatic lesions. Cancer Res. 2016;76(5):1009–18. https://doi.org/10.1158/0008-5472.CAN-15-1423.CrossRefPubMed

101.

Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95. https://doi.org/10.1182/blood-2009-02-206870.CrossRefPubMedPubMedCentral

102.

Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, et al. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 2019;5(11):1582–8. https://doi.org/10.1001/jamaoncol.2019.2792.CrossRefPubMedPubMedCentral

103.

Assenat E, Pageaux GP, Thezenas S, Peron JM, Becouarn Y, Seitz JF, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer. 2019;120(9):896–902. https://doi.org/10.1038/s41416-019-0443-4.CrossRefPubMedPubMedCentral

104.

Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–26. https://doi.org/10.1053/j.gastro.2017.06.007.CrossRefPubMed

105.

Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, et al. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 2019;121(1):22–33. https://doi.org/10.1038/s41416-019-0482-x.CrossRefPubMedPubMedCentral

106.

Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023. https://doi.org/10.1038/s41568-022-00546-2.CrossRefPubMed

107.

Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut. 2023;72(1):129–40. https://doi.org/10.1136/gutjnl-2021-325918.CrossRefPubMed

108.

Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, et al. IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma. Cancer Discov. 2022;12(8):1960–83. https://doi.org/10.1158/2159-8290.CD-20-1628.CrossRefPubMedPubMedCentral

109.

Meyer TMA, Borad MJ, Edeline J, Hausner PF, Hollebecque A, Goyal L, Evans J, Wong KM, Tan BR, Mitry E, Sarker D, Finn R, El-Khoueiry A, Feun LG, El-Rayes B, Thistlethwaite F, Kaseb A, Cirillo C, Noto P, Cristiani S, Sun A, Bruix J, Sangro B, editor. Overall safety and efficacy from the phase 1 trial of ADP-A2AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma or other cancer types expressing alpha-fetoprotein. In: ILCA 16th annual conference; 2022 1–4 September 2022; Madrid, Spain.

110.

Zhao Z, Guo W, Fang S, Song S, Song J, Teng F, et al. An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: a phase I trial. J Clin Oncol. 2021;39(15_suppl):4095. https://doi.org/10.1200/JCO.2021.39.15_suppl.4095.CrossRef

111.

Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979–89. https://doi.org/10.1158/1078-0432.CCR-19-3259.CrossRefPubMed

112.

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. https://doi.org/10.1038/nrdp.2016.18.CrossRefPubMed

113.

Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7(1):267. https://doi.org/10.1186/s40425-019-0749-z.CrossRefPubMedPubMedCentral

Titel: New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
verfasst von: John D. Gordan
Bridget P. Keenan
Huat Chye Lim
Mark Yarchoan
R. Katie Kelley
Publikationsdatum: 04.07.2023
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2023
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-023-01907-3

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Efbemalenograstim Alfa: First Approval

Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management

Beremagene Geperpavec: First Approval

Fezolinetant: First Approval

Pharmacologic Management of Cancer-Related Pain in Pregnant Patients

Correction to: Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study